Viewing Email: 20100407-063123_62172.eml [13KB]

Date / Time: April 7th, 2010 3:31 AM
From: 'achaogen' <caton@purecommunicationsinc.com>
To: 'yale graduate school alumni in the dc area' <hbiden@senecaga.com>
Subject: Achaogen Completes $56 Million Series C Financing
Tags: Add A tag

Email Header Data:

IP Addresses found: 72.32.253.68 / 72.32.253.161 / 72.32.253.161 / 72.32.253.11 / 216.128.70.102 / 216.128.70.102
Thread-Index: AdhhoyedsSVKka/nT8CDcoCrQMif7w==
Delivered-To: hbiden@rosemontseneca.com
Received: by 10.213.3.4 with SMTP id 4cs68290ebl; Wed, 7 Apr 2010 03:31:34 -0700 (PDT)
X-MimeOLE: Produced By Microsoft MimeOLE
Content-class: urn:content-classes:message
Received: by 10.231.156.205 with SMTP id y13mr3970739ibw.27.1270636292568; Wed, 07 Apr 2010 03:31:32 -0700 (PDT)
Importance: normal
Priority: normal
Return-Path: <business.wire@osimail2.us>
Received: from server514.appriver.com (server514a.exghost.com [72.32.253.68]) by mx.google.com with ESMTP id k24si31542980ibr.30.2010.04.07.03.31.31; Wed, 07 Apr 2010 03:31:31 -0700 (PDT)
Received-SPF: fail (google.com: domain of business.wire@osimail2.us does not designate 72.32.253.68 as permitted sender) client-ip=72.32.253.68;
Authentication-Results: mx.google.com; spf=hardfail (google.com: domain of business.wire@osimail2.us does not designate 72.32.253.68 as permitted sender) smtp.mail=business.wire@osimail2.us
X-Policy: GLOBAL - UNKNOWN
X-Primary: business.wire@osimail2.us
X-Note: This Email was scanned by AppRiver SecureTide
X-Virus-Scan: V-
X-Note-SnifferID: 0
X-Note: TCH-CT/SI:0-20/SG:2 4/7/2010 5:30:40 AM
X-GBUdb-Analysis: 0, 72.32.253.161, Ugly c=0.789716 p=-0.915453 Source White
X-Signature-Violations: 0-0-0-15621-c
X-Note: Spam Tests Failed:
X-Country-Path: ->UNITED STATES->PRIVATE->UNITED STATES->UNITED STATES->UNITED STATES
X-Note-Sending-IP: 72.32.253.161
X-Note-Reverse-DNS: fe06.exg4.exghost.com
X-Note-WHTLIST: business.wire@osimail2.us
X-Note: User Rule Hits:
X-Note: Global Rule Hits: G179 G180 G181 G182 G186 G187 G285
X-Note: Encrypt Rule Hits:
X-Note: Mail Class: VALID
X-Note: Headers Injected
Received: from [72.32.253.161] (HELO FE06.exg4.exghost.com) by server514.appriver.com (CommuniGate Pro SMTP 5.3.2) with ESMTP id 110504035 for hbiden@rosemontseneca.com; Wed, 07 Apr 2010 05:31:31 -0500
Received: from outbound.appriver.com ([72.32.253.11]) by FE06.exg4.exghost.com with Microsoft SMTPSVC(6.0.3790.3959); Wed, 7 Apr 2010 05:31:30 -0500
Received: from [10.242.229.2] (HELO inbound.appriver.com) by outbound.appriver.com (CommuniGate Pro SMTP 5.3.2) with ESMTP id 320142728 for hbiden@senecaga.com; Wed, 07 Apr 2010 05:31:31 -0500
X-Policy: senecaga.com
X-Primary: hbiden@senecaga.com
X-Note: This Email was scanned by AppRiver SecureTide
X-Virus-Scan: V-
X-Note-SnifferID: 0
X-Note: TCH-CT/SI:0-20/SG:2 4/7/2010 5:30:57 AM
X-GBUdb-Analysis: 0, 216.128.70.102, Ugly c=0 p=0 Source New
X-Signature-Violations: 0-0-0-14238-c
X-Note: Spam Tests Failed:
X-Country-Path: ->UNITED STATES->UNITED STATES
X-Note-Sending-IP: 216.128.70.102
X-Note-Reverse-DNS: mo3.osimail2.us
X-Note-WHTLIST: business.wire@osimail2.us
X-Note: User Rule Hits:
X-Note: Global Rule Hits: G179 G180 G181 G182 G186 G187 G285
X-Note: Encrypt Rule Hits:
X-Note: Mail Class: VALID
X-Note: Headers Injected
Received: from mo3.osimail2.us ([216.128.70.102] verified) by inbound.appriver.com (CommuniGate Pro SMTP 5.2.16) with SMTP id 49416137 for hbiden@senecaga.com; Wed, 07 Apr 2010 05:31:30 -0500
Received: from v3 by mo3.osimail2.us for hbiden@senecaga.com; Wed, 7 Apr 2010 06:31:23 -0400
Message-ID: <07DA040702A3061F17EC@mo3.osimail2.us>
Subject: Achaogen Completes $56 Million Series C Financing
From: "Achaogen" <caton@purecommunicationsinc.com>
x-mid: 2161-6081800-78
Date: Wed, 7 Apr 2010 06:31:23 -0400
MIME-Version: 1.0
To: <hbiden@senecaga.com>
X-Mailer: Copia emailFacts v7.261
Content-Type: text/html;
charset="us-ascii"
Content-Transfer-Encoding: 7bit
Return-Path: <business.wire@osimail2.us>
X-OriginalArrivalTime: 07 Apr 2010 10:31:30.0578 (UTC) FILETIME=[7CA15F20:01CAD63D]
--><meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1" /><meta name="description" content="SAN FRANCISCO--(BUSINESS WIRE)-- Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, " /><meta name="keywords" content="United States, North America, Health, Biotechnology, Clinical Trials, Infectious Diseases, California, Pharmaceutical, Funding" /><meta name="ThisRevisionCreated" content="20100407T103000+0000" /><meta name="NewsItemID" content="20100407005434" /><meta name="RevisionId" content="1" /><title>Achaogen Completes $56 Million Series C Financing</title><style type="text/css"><!--
Content: TEXT/HTML
April 7, 2010 10:30 UTC
Achaogen Completes $56 Million Series C Financing
Proceeds Will Continue to Advance Clinical Development of Novel Antibiotics to Combat Multi-Drug Resistant Gram-Negative Bacteria and MRSA
SAN FRANCISCO--(BUSINESS WIRE)-- Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was led by new investor Frazier Healthcare Ventures, and also included new investor Alta Partners. Current investors 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust also participated in the round. In conjunction with this financing, Robert More, general partner, Frazier Healthcare Ventures, will join the Achaogen board of directors.
“We appreciate the strong support of our existing investors and are pleased to welcome Frazier Healthcare Ventures and Alta Partners to the Achaogen team,” stated Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “Our mission is to discover and develop life-saving antibiotics. This financing together with non-dilutive capital that we have secured through partnerships with various government agencies will enable us to advance multiple clinical programs, including conducting a Phase 2 study in complicated urinary tract infections of ACHN-490, our lead candidate for multi-drug resistant bacterial infections.”
“Frazier Healthcare is excited to work with Alta Partners and Achaogen’s existing investors to support the company’s growth,” said Robert More, general partner, Frazier Healthcare. “Achaogen combines excellent science with a compelling business model, blending venture capital and non-dilutive financing to advance multiple programs that have potential to address the increasing dire need for new agents to treat multi-drug resistant bacteria worldwide.”
Mr. More is a member of Frazier Healthcare’s biopharma and medical device investment teams. Prior to Frazier Healthcare, Mr. More was a partner with Domain Associates. He has also served as the chief operating officer of Small Molecule Therapeutics. Mr. More has served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), Onux Medical (acquired by C.R. Bard), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan) and IntraLase (acquired by Advanced Medical Optics, Inc.).
About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today that will combat tomorrow’s resistant pathogens. Through the use of non-dilutive funding from partnerships with the NIH and Department of Defense to augment funding from venture investors, Achaogen has established specialized capabilities that have enabled the company to pursue multiple discovery and development programs. The company’s most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
For more information, please visit the company’s website at www.achaogen.com.

Contacts
Pure Communications
Ashlea Kosikowski, 910-547-7093

Source: Achaogen
View this news release online at:
http://www.businesswire.com/news/home/20100407005434/en
conversation-id 112953 date-last-viewed 0 date-received 1270636291 flags 8606972929 remote-id 10735
Loaded in 0 Seconds